Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DS4U1W
|
|||
| Drug Name |
Ligelizumab
|
|||
| Synonyms |
QGE031
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Chronic idiopathic urticaria [ICD-11: EB00.1; ICD-10: L50.1; ICD-9: 708] | Phase 3 | [1] | |
| Company |
Novartis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Immunoglobulin E (IgE) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04210843) Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Novartis. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.